Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma

Lancet Oncol. 2021 Aug;22(8):e342. doi: 10.1016/S1470-2045(21)00326-0.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Ipilimumab / adverse effects
  • Melanoma* / drug therapy
  • Nivolumab / adverse effects

Substances

  • Ipilimumab
  • Nivolumab